X

Alembic Pharmaceuticals Ltd Stock Analysis

Mid Cap
Evaluated by 3246 users | BSE: 533573 | NSE: APLLTD |
Pharmaceuticals & Drugs

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one...

1. Right Stock
Very Good
2. Right Price
3. Right Time

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alembic Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
Value Creation Index Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 16.87%23.36%24.68%33.08%30.54%50.31%22.18%15.92%17.18%19.81%
Value Creation Index 0.471.031.151.881.663.370.930.380.490.72
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1,2021,4651,5201,8632,0563,1663,1353,1303,9354,606
Y-o-Y Gr. Rt.-21.9%3.8%22.6%10.4%54%-1%-0.1%25.7%17.1%
Adjusted EPS (Rs.) 15.647.118.5212.5515.5237.9521.5820.6530.1845.15
Y-o-Y Gr. Rt.--54.5%19.8%47.3%23.7%144.5%-43.1%-4.3%46.2%49.6%
Book Value per Share (Rs.) 49.120.9526.6835.8446.9384.74100.92117.78144.24170.79
Adjusted Net Profit 86134161237293715407389569851
Net Op. Cash Flow (Rs. Cr.) 95142265240172948329312812449
Debt to Cash Flow from Ops 3.452.490.710.461.530.120.272.271.393.89
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Alembic Pharmaceuticals Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 16.1%17.5%13.7%17.1%
Adjusted EPS 12.5%23.8%27.9%49.6%
Book Value per Share 14.929.519.218.4
Share Price 43.6% 9.4% 21.6% 63.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 2938.7535.7740.1637.557.6523.2518.8823.0428.67
Operating Profit Margin (%) 11.9815.1816.3519.3619.2231.7519.8219.6621.7526.36
Net Profit Margin (%) 7.169.1510.5612.713.5522.613.112.714.6717.87
Debt to Equity 1.210.890.370.160.30.070.050.320.420.54
Working Capital Days 0158175163168121140180168171
Cash Conversion Cycle 0584539471226323869
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 69.78%
Institutions 17.10%
Non-Institutions 13.12%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Alembic Pharmaceuticals Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Alembic Pharmaceuticals Ltd is a good quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Alembic Pharmaceuticals Ltd's performance infers:

Alembic Pharmaceuticals Ltd earnings have grown by 23.8%, whereas share price has appreciated 9.4% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

Data is not available for this company

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

  • Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
  • 1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
  • The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
  • The company’s MDs honoured with 'Transformational Leader Award'
  • The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
  • The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'

Milestones

  • 1907: Started manufacturing tinctures and alcohol at Vadodara.
  • 1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
  • 1961: Lal bahadur Shastri inaugurates the Penicillin plant.
  • 1967: Bulk manufacturing of Vitamin B12.
  • 1971: Erythromycin manufactured for the first time in India.
  • 1972: Althrocin a brand of Erythromycin launched.
  • 1997: Althrocin becomes top selling brand in India.
  • 1999: Alembic starts production of synthetic organic API.
  • 2000: Gets ISO 14000 certification for its facilities at Vadodara.
  • 2001: Starts manufacturing of Cephalosporin C.
  • 2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
  • 2009: Addressed chronic therapies through multiple marketing divisions.
  • 2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
  • 2011: Pharmaceutical Business demerged from Alembic - APL Listed.
  • 2012: Launched Dermatology division in domestic market with 8 products.
  • 2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
  • 2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
  • 2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
  • 2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
  • 2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
  • 2017: Acquired Orit Laboratories LLC, USA.
  • 2018: FDA approved Aleor’s dermatology facility.
  • 2018: Highest ever investment commitment across four new manufacturing facilities.
  • 2019: FDA approves Oncology oral solid facility.
  • 2019: Formed a JV, to enter China.
  • 2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback